首页> 美国卫生研究院文献>Frontiers in Pharmacology >Anti-Inflammatory Effect of a TCM Formula Li-Ru-Kang in Rats With Hyperplasia of Mammary Gland and the Underlying Biological Mechanisms
【2h】

Anti-Inflammatory Effect of a TCM Formula Li-Ru-Kang in Rats With Hyperplasia of Mammary Gland and the Underlying Biological Mechanisms

机译:中药复方李汝康对乳腺增生大鼠的抗炎作用及其生物学机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Li-Ru-Kang (LRK), a formula of eight traditional Chinese medicines (TCM), has been used to treat hyperplasia of mammary gland (HMG) in TCM clinics. However, how LRK works in HMG patients is unclear. To explore the possible mechanisms of LRK against HMG, the network pharmacology was used to screen the potential targets and possible pathways that involved in LRK treated HMG. Rat HMG model induced by estrogen and progesterone was used to further verify the effects of the key molecules of LRK selected from the enriched pathways on HMG. Nipple heights and diameters were measured and uterus index was calculated. The histopathological changes of mammary gland tissue were detected by hematoxylin-eosin (H&E) staining. Western blot was used to detect the phosphorylation of ERK, JNK, and P38. And immunohistochemistry staining was performed to evaluate the levels of estrogen receptor α (ERα), progesterone receptor (PR), nuclear factor-(NF-)κB (p65), interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), cyclooxygenases 2 (COX-2), inducible nitric oxide synthase (iNOS), 8-hydroxy-2′deoxyguanosine (8-OHdG), and nitrotyrosine (NT). Our results indicate that LRK treatment rescues significantly nipples height and diameter, decreases uterus index and ameliorates HMG. LRK treatment also markedly attenuates the over-expression of IL-1β, TNF-α, COX-2, and iNOS, and suppressed the formation of 8-OHdG and NT. Furthermore, LRK treatment significantly inhibits the phosphorylation of JNK, ERK, and p38 and expression of NF-κB (p65), interestingly, LRK treatment has no effect on the expression of ERα and PR. Our data suggest that the LRK treatment protects the mammary glands from the damage of oxidative stress and inflammation induced by estrogen and progesterone, via suppresses of MAPK/NF-κB signaling pathways without affecting on the expression of ERα and PR.
机译:Li-Ru-Kang(LRK)是八种中药(TCM)的配方,已在中医诊所用于治疗乳腺增生(HMG)。但是,LRK在HMG患者中的作用尚不清楚。为了探索LRK对抗HMG的可能机制,使用网络药理学来筛选参与LRK治疗的HMG的潜在靶标和可能的途径。用雌激素和孕激素诱导的大鼠HMG模型进一步验证了从富集途径中选择的LRK关键分子对HMG的作用。测量乳头的高度和直径,并计算子宫指数。用苏木精-伊红(H&E)染色检测乳腺组织的组织病理学变化。 Western印迹用于检测ERK,JNK和P38的磷酸化。并进行免疫组化染色以评估雌激素受体α(ERα),孕激素受体(PR),核因子-(NF-)κB(p65),白介素-1β(IL-1β),肿瘤坏死因子α(TNF)的水平-α),环氧合酶2(COX-2),诱导型一氧化氮合酶(iNOS),8-羟基-2'脱氧鸟苷(8-OHdG)和硝基酪氨酸(NT)。我们的结果表明,LRK治疗可明显挽救乳头的高度和直径,降低子宫指数并改善HMG。 LRK处理还可以显着减弱IL-1β,TNF-α,COX-2和iNOS的过表达,并抑制8-OHdG和NT的形成。此外,LRK处理显着抑制JNK,ERK和p38的磷酸化以及NF-κB(p65)的表达,有趣的是,LRK处理对ERα和PR的表达没有影响。我们的数据表明,LRK治疗可通过抑制MAPK /NF-κB信号通路来保护乳腺免受由雌激素和孕激素引起的氧化应激和炎症的损害,而不影响ERα和PR的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号